A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies
A phase 1/2 trial of EP0031 and Pemetrexed in non-small-cell lung cancer, run by Ellipses Pharma, now recruiting.
Overview
A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies is a phase 1/2 interventional study registered as NCT05443126 by Ellipses Pharma, with 265 participants planned, started 2022-09-30 and due to reach its primary completion in 2027-03. Interventions recorded: EP0031, Platinum chemotherapy and Pemetrexed.
Similar pages
not linked directly; found by shared links- TrialA Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Shares Pemetrexed, Non-small-cell lung cancer and the tag pipeline.
- TreatmentEP0062
Shares Ellipses Pharma and the tag pipeline.
- TrialA Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
Shares Pemetrexed, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy to Evaluate the Safety and Tolerability of EP0042
Shares Ellipses Pharma and the tag pipeline.
- TrialA Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients
Shares Pemetrexed, Non-small-cell lung cancer and the tag pipeline.
- TrialASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
Shares Pemetrexed, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Shares Pemetrexed, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
Shares Pemetrexed, Non-small-cell lung cancer and the tag pipeline.